Iteriontherapeutics
2 known investors
Iterion Therapeutics is a clinical-stage biopharmaceutical company developing Tegavivint, a targeted Wnt/β-catenin inhibitor for cancers with Wnt-driven mutations, primarily hepatocellular carcinoma and colorectal cancer. The drug works by blocking β-catenin's oncogenic activity through TBL1 inhibition while minimizing the toxicities associated with upstream Wnt inhibitors.
BiotechMedical Devices